Looks like decision to raise capital to reduce debt and the decision not to list biologics as a separate company has led to a re-rating…
Onwards and upwards..Debt was huge and was clearly the reason for underperformance…
1 Like
1 Like
Biocon strategy to position Bio similars working out . but pace of growth is not to markets satisfaction. Their plan to bring Poonawala as investor and pivot to vaccines sounded very strategic bt has moved needle in terms of business . Syngene has disappointed in many ways and new leadership expected to revisiit many past strategic mis steps . For investors who have been with Biocon for long its quite a testing time
Malolan
1 Like